Efficacy & Safety Study of VESIcare® (Solifenacin Succinate) in Patients Wishing to Switch From Detrol LA® for Treatment of Overactive Bladder

NCT00454740 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

441

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder, Overactive

Interventions

DRUG: solifenacin succinate

Sponsor

Astellas Pharma Inc